Literature DB >> 28439916

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

Loic Ysebaert1, Thérèse Aurran-Schleinitz2, Caroline Dartigeas3, Marie-Sarah Dilhuydy4, Pierre Feugier5, Anne-Sophie Michallet6, Olivier Tournilhac7, Jehan Dupuis8, Pierre Sinet9, Claire Albrecht9, Florence Cymbalista10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28439916     DOI： 10.1002/ajh.24773

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  9 in total

1.  Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy.

Authors:  Serhat Çelik; Leylagül Kaynar; Zeynep Tuğba Güven; Mustafa Baydar; Muzaffer Keklik; Mustafa Çetin; Ali Ünal; Fatih Demirkan
Journal:  Indian J Hematol Blood Transfus       Date:  2021-07-03       Impact factor: 0.900

Review 2.  Ibrutinib dose modifications in the management of CLL.

Authors:  Camille Hardy-Abeloos; Rachel Pinotti; Janice Gabrilove
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

Review 3.  Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Authors:  Bartosz Puła; Aleksandra Gołos; Patryk Górniak; Krzysztof Jamroziak
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

4.  Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Authors:  Anıl Tombak; Funda Pepedil Tanrıkulu; Salih Sertaç Durusoy; Hüseyin Derya Dinçyürek; Emin Kaya; Elif Gülsüm Ümit; İrfan Yavaşoğlu; Özgür Mehtap; Burak Deveci; Mehmet Ali Özcan; Hatice Terzi; Müfide Okay; Nilgün Sayınalp; Mehmet Yılmaz; Vahap Okan; Alperen Kızıklı; Ömer Özcan; Güven Çetin; Sinan Demircioğlu; İsmet Aydoğdu; Güray Saydam; Eren Arslan Davulcu; Gül İlhan; Mehmet Ali Uçar; Gülsüm Özet; Seval Akpınar; Burhan Turgut; İlhami Berber; Erdal Kurtoğlu; Mehmet Sönmez; Derya Selim Batur; Rahşan Yıldırım; Vildan Özkocamaz; Ahmet Kürşad Güneş; Birsen Sahip; Şehmus Ertop; Olga Meltem Akay; Abdülkadir Baştürk; Mehmet Hilmi Doğu; Aydan Akdeniz; Ali Ünal; Ahmet Seyhanlı; Emel Gürkan; Demet Çekdemir; Burhan Ferhanoğlu
Journal:  Turk J Haematol       Date:  2021-08-27       Impact factor: 1.831

5.  Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients.

Authors:  Caroline Protin; Florence Abravanel; Laurent Alric; Suzanne Tavitian; Lucie Obéric; Jacques Izopet; Guillaume Martin-Blondel; Loic Ysebaert
Journal:  Open Forum Infect Dis       Date:  2019-07-28       Impact factor: 3.835

6.  Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.

Authors:  Gilles Salles; Emmanuel Bachy; Lukas Smolej; Martin Simkovic; Lucile Baseggio; Anna Panovska; Hervé Besson; Nollaig Healy; Jamie Garside; Wafae Iraqi; Joris Diels; Corinna Pick-Lauer; Martin Spacek; Renata Urbanova; Daniel Lysak; Ruben Hermans; Jessica Lundbom; Evelyne Callet-Bauchu; Michael Doubek
Journal:  Ann Hematol       Date:  2019-11-19       Impact factor: 3.673

7.  Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience.

Authors:  Alessandro Broccoli; Lisa Argnani; Alice Morigi; Laura Nanni; Beatrice Casadei; Cinzia Pellegrini; Vittorio Stefoni; Pier Luigi Zinzani
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

8.  Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Authors:  Alessandra Tedeschi; Anna Maria Frustaci; Francesca Romana Mauro; Annalisa Chiarenza; Marta Coscia; Stefania Ciolli; Gianluigi Reda; Luca Laurenti; Marzia Varettoni; Roberta Murru; Claudia Baratè; Paolo Sportoletti; Antonino Greco; Chiara Borella; Valentina Rossi; Marina Deodato; Annalisa Biagi; Giulia Zamprogna; Angelo Curto Pelle; Gianfranco Lapietra; Candida Vitale; Francesca Morelli; Ramona Cassin; Alberto Fresa; Chiara Cavalloni; Massimiliano Postorino; Claudia Ielo; Roberto Cairoli; Francesco Di Raimondo; Marco Montillo; Giovanni Del Poeta
Journal:  Blood Adv       Date:  2021-12-28

Review 9.  Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.

Authors:  Lina van der Straten; Paul J Hengeveld; Arnon P Kater; Anton W Langerak; Mark-David Levin
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.